PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
The News International ... “Chromosome analysis of children presenting with disorders of sex development” by Ms. Shamsa Kanwal for M.Phil (Human Genetics), “In vitro efficacy of combinations of ceftazidime with meropenem, ceftazidime with piperacillin , ceftazidime with ... and more »
FinanzNachrichten.de (Pressemitteilung) ... zeigte Ceftobiprol darüber hinaus eine vergleichbar hohe Aktivität wie Cefepime und Ceftazidime , zwei häufig verwendete Breitband-Cephalosporin-Antibiotika, denen jedoch die Anti-MRSA-Aktivität fehlt, über die Ceftobiprol zusätzlich zu seinem ...
PR Newswire (press release) ... Enterobacteriaceae. Interviewed thought leaders also expect Forest/AstraZeneca's ceftazidime /avibactam and Cubist's ceftolozane/tazobactam to offer improvements in activity against multidrug-resistant P. aeruginosa, compared to current HAP therapies. and more »
